Compositions and methods for treatment of edema

Patent metadata

Field	Value
Publication number	US-10874651-B2
Application number	US-201916277942-A
Country	US
Kind code	B2
Filing date	Feb 15, 2019
Priority date	Feb 5, 2015
Publication date	Dec 29, 2020
Grant date	Dec 29, 2020

Abstract

Provided are pharmaceutical compositions and methods of treating or preventing edema, using an anti-T cell agent, an anti-TGF-β1 agent, or an anti-angiotensin agent, preferably a combination of at least two such agents. The pharmaceutical compositions can be formulated for systemic or local administration, and are preferably administered topically.

First claim

The invention claimed is:

1. A method of treating lymphedema, the method comprising administering to a subject with lymphedema a pharmaceutical composition comprising an effective amount of pirfenidone.

2. The method of claim 1 , wherein the pharmaceutical composition is administered topically.

3. The method of claim 2 , wherein the pharmaceutical composition is in a form selected from the group consisting of an ointment, a cream, a lotion, a paste, a gel, a mousse, a foam, a lacquer, a suspension, a liquid, and a spray.

4. The method of claim 3 , wherein the pharmaceutical composition is in the form of an ointment.

5. The method of claim 2 , wherein the pharmaceutical composition is administered at least once a day.

6. The method of claim 5 , wherein the pharmaceutical composition is administered at least twice a day.

7. The method of claim 1 , wherein the pharmaceutical composition is administered orally.

8. The method of claim 7 , wherein the pharmaceutical composition is in a form selected from the group consisting of a tablet, a capsule, a liquid, a solution, a softgel, a suspension, an emulsion, a syrup, and an elixir.

9. The method of claim 8 , wherein the pharmaceutical composition is in the form of a tablet or a capsule.

10. The method of claim 7 , wherein the pharmaceutical composition is administered at least once a day.

11. The method of claim 10 , wherein the pharmaceutical composition is administered at least twice a day.

12. A method of preventing lymphedema, the method comprising administering to a subject at risk of or susceptible to developing lymphedema a pharmaceutical composition comprising an effective amount of pirfenidone, wherein the pharmaceutical composition is administered prophylactically within about six weeks of a lymphatic injury.

13. The method of claim 12 , wherein the pharmaceutical composition is administered prophylactically within about two weeks of a lymphatic injury.

14. The method of claim 12 , wherein the pharmaceutical composition is administered topically.

15. The method of claim 14 , wherein the pharmaceutical composition is in a form selected from the group consisting of an ointment, a cream, a lotion, a paste, a gel, a mousse, a foam, a lacquer, a suspension, a liquid, and a spray.

16. The method of claim 15 , wherein the pharmaceutical composition is in the form of an ointment.

17. The method of claim 14 , wherein the pharmaceutical composition is administered at least once a day.

18. The method of claim 17 , wherein the pharmaceutical composition is administered at least twice a day.

19. The method of claim 12 , wherein the pharmaceutical composition is administered orally.

20. The method of claim 19 , wherein the pharmaceutical composition is in a form selected from the group consisting of a tablet, a capsule, a liquid, a solution, a softgel, a suspension, an emulsion, a syrup, and an elixir.

21. The method of claim 20 , wherein the pharmaceutical composition is in the form of a tablet or a capsule.

22. The method of claim 19 , wherein the pharmaceutical composition is administered at least once a day.

23. The method of claim 22 , wherein the pharmaceutical composition is administered at least twice a day.

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• Mehrara Babak
• Gardenier Jason
• Savetsky Ira
• Aras Omer

Classifications

• A61P7/10

  Antioedematous agents; Diuretics · CPC title

• A61K31/4418 Primary

  having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine · CPC title

• A61K9/0014 Primary

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/401

  Proline; Derivatives thereof, e.g. captopril · CPC title